BioMark Diagnostics (TSE:BUX)
:BUX
Top Page
BioMark Diagnostics
(BUX)
Select Model
Select Model
Rating:48Neutral
Price Target:
C$0.59
▲(29.13% Upside)
Action:ReiteratedDate:03/25/26
The score is held down primarily by weak financial performance (early/revenue-light profile, large losses, and ongoing cash burn with elevated financing risk). Technicals are a partial offset due to a constructive longer-term trend and positive MACD, but near-term momentum indicators remain soft. Valuation is not supportive given the negative P/E and lack of dividend yield.
Positive Factors
Focused diagnostics business
BioMark operates in a durable, high-barrier niche: blood-based diagnostics and biomarker discovery for early disease detection. This business model, if clinically validated, can create recurring revenue streams and strong clinical/IP moats that sustain growth over multiple years.
Negative Factors
Very small, declining revenue
A tiny and falling revenue base undermines economies of scale and delays margin expansion; it constrains reinvestment capacity and increases dependence on external funding. Sustained top-line weakness makes it harder to achieve profitable, self-funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused diagnostics business
BioMark operates in a durable, high-barrier niche: blood-based diagnostics and biomarker discovery for early disease detection. This business model, if clinically validated, can create recurring revenue streams and strong clinical/IP moats that sustain growth over multiple years.
Read all positive factors
BioMark Diagnostics (BUX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$63.05M
Dividend YieldN/A
Average Volume (3M)16.46K
Price to Earnings (P/E)―
Beta (1Y)0.12
Revenue Growth-21.89%
EPS Growth26.36%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding105,090,210
10 Day Avg. Volume19,330
30 Day Avg. Volume16,464
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)-41.95
Price to Sales (P/S)156.67
P/FCF Ratio-25.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioMark Diagnostics Business Overview & Revenue Model
Company Description
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to...
How the Company Makes Money
null...
BioMark Diagnostics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2024 | Jun 2022 | Jun 2021 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 91.77K | 154.22K | 153.49K | 43.93K | 0.00 | 263.28K |
| Gross Profit | -135.75K | 154.22K | -232.70K | 43.93K | -13.69K | 263.28K |
| EBITDA | -1.29M | -1.46M | -1.35M | -1.22M | -1.08M | -1.20M |
| Net Income | -1.70M | -1.93M | -1.84M | -1.45M | -1.09M | -1.22M |
Balance Sheet | ||||||
| Total Assets | 2.14M | 3.13M | 732.29K | 1.47M | 952.94K | 637.29K |
| Cash, Cash Equivalents and Short-Term Investments | 1.29M | 2.48M | 72.04K | 382.71K | 877.68K | 611.80K |
| Total Debt | 711.78K | 454.16K | 823.87K | 1.05M | 119.32K | 8.66K |
| Total Liabilities | 1.63M | 1.39M | 1.88M | 2.11M | 1.03M | 1.08M |
| Stockholders Equity | 508.03K | 1.74M | -1.15M | -635.69K | -79.09K | -439.13K |
Cash Flow | ||||||
| Free Cash Flow | -2.05M | -1.10M | -919.72K | -1.26M | -455.55K | -454.57K |
| Operating Cash Flow | -1.42M | -1.09M | -914.42K | -1.20M | -455.55K | -453.79K |
| Investing Cash Flow | -1.43M | -3.53K | -5.30K | -59.20K | -3.20K | -790.00 |
| Financing Cash Flow | 3.25M | 3.42M | 609.05K | 768.16K | 724.63K | 1.05M |
BioMark Diagnostics Technical Analysis
Neutral
0.46
Price Trends
0.56
Positive
0.50
Positive
0.42
Positive
Market Momentum
<0.01
Positive
49.04
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BUX, the sentiment is Neutral. The current price of 0.46 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.56, and above the 200-day MA of 0.42, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.04 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:BUX.
BioMark Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$415.44M | -37.02 | ― | ― | 34.85% | -62.50% | |
48 Neutral | C$63.05M | -32.47 | ― | ― | -21.89% | 26.36% | |
43 Neutral | C$5.32M | -2.38 | -9999.00% | ― | ― | 19.05% | |
41 Neutral | C$33.74M | -21.43 | -434.25% | ― | ― | 10.97% |
* Healthcare Sector Average
TSE:BUX
BioMark Diagnostics
0.60
0.34
130.77%
TSE:EDT
Spectral Medical
1.42
0.72
102.86%
TSE:TELO
Telo Genomics Corp
0.05
-0.05
-47.00%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:ZYUS
ZYUS Life Sciences
0.57
-0.21
-26.92%
TSE:SONA
Sona Nanotech Inc
0.30
0.03
13.46%
BioMark Diagnostics Corporate Events
Business Operations and Strategy
BioMark Wins Peer-Reviewed Validation for AI-Driven Lung Cancer Detection Model
Positive
Jan 15, 2026
BioMark Diagnostics has achieved a key validation milestone with the acceptance of its machine learning-driven lung cancer detection research for publication in the peer-reviewed journal Frontiers in Oncology. Developed in collaboration with Harri...
Business Operations and Strategy
BioMark Wins Peer-Reviewed Validation for AI-Driven Lung Cancer Detection Model
Positive
Jan 15, 2026
BioMark Diagnostics has achieved a key validation milestone with the acceptance of its machine learning-driven lung cancer detection research for publication in the peer-reviewed journal Frontiers in Oncology. Developed in collaboration with Harri...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
BioMark Leverages Landmark Lung Cancer Studies and New Funding to Drive 2026 Expansion
Positive
Dec 31, 2025
BioMark Diagnostics reported a transformative 2025 marked by major capacity expansion, clinical validation and growing industry recognition, as it doubled laboratory throughput, bolstered its technical team, advanced AI/ML capabilities, and comple...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
BioMark Adds AI-Focused Investor James Lavender to Board to Drive U.S. Expansion
Positive
Dec 30, 2025
BioMark Diagnostics has appointed technology investor and AI-focused growth strategist James Lavender to its board of directors following approval at the company’s recent annual general meeting. Lavender, a major participant in BioMark’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.